1168 related articles for article (PubMed ID: 33321019)
1. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
Leclercq S; de Timary P; Stärkel P
Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
[TBL] [Abstract][Full Text] [Related]
2. Microbiota-based treatments in alcoholic liver disease.
Sung H; Kim SW; Hong M; Suk KT
World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
[TBL] [Abstract][Full Text] [Related]
3. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Hong M; Han DH; Hong J; Kim DJ; Suk KT
Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
[TBL] [Abstract][Full Text] [Related]
4. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
[TBL] [Abstract][Full Text] [Related]
5. Alcohol, liver disease and the gut microbiota.
Bajaj JS
Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
[TBL] [Abstract][Full Text] [Related]
6. Alcohol or Gut Microbiota: Who Is the Guilty?
Meroni M; Longo M; Dongiovanni P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
[TBL] [Abstract][Full Text] [Related]
7. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
Huang W; Kong D
Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
[TBL] [Abstract][Full Text] [Related]
8. Microbiome as a therapeutic target in alcohol-related liver disease.
Sarin SK; Pande A; Schnabl B
J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
[TBL] [Abstract][Full Text] [Related]
9. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
[TBL] [Abstract][Full Text] [Related]
10. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease.
Dubinkina VB; Tyakht AV; Odintsova VY; Yarygin KS; Kovarsky BA; Pavlenko AV; Ischenko DS; Popenko AS; Alexeev DG; Taraskina AY; Nasyrova RF; Krupitsky EM; Shalikiani NV; Bakulin IG; Shcherbakov PL; Skorodumova LO; Larin AK; Kostryukova ES; Abdulkhakov RA; Abdulkhakov SR; Malanin SY; Ismagilova RK; Grigoryeva TV; Ilina EN; Govorun VM
Microbiome; 2017 Oct; 5(1):141. PubMed ID: 29041989
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
12. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
14. Microbiota, a key player in alcoholic liver disease.
Cassard AM; Ciocan D
Clin Mol Hepatol; 2018 Jun; 24(2):100-107. PubMed ID: 29268595
[TBL] [Abstract][Full Text] [Related]
15. Targeting Dysbiosis for the Treatment of Liver Disease.
Anand G; Zarrinpar A; Loomba R
Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
[TBL] [Abstract][Full Text] [Related]
16. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
17. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
[TBL] [Abstract][Full Text] [Related]
19. Fecal microbiota transplantation in alcohol related liver diseases.
Shasthry SM
Clin Mol Hepatol; 2020 Jul; 26(3):294-301. PubMed ID: 32570299
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
